RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
brief summary
This is a randomized, controlled, open-label, multicenter Phase II/III study evaluating the efficacy and safety of RC118 (an antibody-drug conjugate targeting Claudin 18.2) in combination with RC148 versus PD-1 inhibitor (Tislelizumab) plus chemotherapy (CAPOX) as first-line treatment in patients with Claudin 18.2-positive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The study consists of two phases: Phase II will explore the optimal dose combination of RC118 and RC148 across three experimental arms versus a standard comparator arm. Phase III will evaluate the efficacy (progression-free survival) of the recommended Phase III dose (RP3D) combination versus standard of care.
official title
A Randomized, Controlled, Open-Label, Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of RC118 in Combination With RC148 Versus PD-1 Inhibitor Plus Chemotherapy as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Locally Advanced Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma